Annals of Surgical Oncology最新文献

Predictors of Response to Neoadjuvant Systemic Therapy and Survival in Patients with cN1 Breast Cancer. cN1乳腺癌患者对新辅助全身治疗的反应和生存的预测因素。

IF 3.8 2区医学

Annals of Surgical Oncology Pub Date : 2026-11-07 DOI: 10.1245/s10434-026-20848-1

Jennifer H Chen, Kelly K Hunt, Ronald Rauch, Mary S Guirguis, Helen M Johnson, Matthew J Piotrowski, Taiwo Adesoye, Nina Tamirisa, Puneet Singh, Susie X Sun

{"title":"Predictors of Response to Neoadjuvant Systemic Therapy and Survival in Patients with cN1 Breast Cancer.","authors":"Jennifer H Chen, Kelly K Hunt, Ronald Rauch, Mary S Guirguis, Helen M Johnson, Matthew J Piotrowski, Taiwo Adesoye, Nina Tamirisa, Puneet Singh, Susie X Sun","doi":"10.1245/s10434-026-20848-1","DOIUrl":"https://doi.org/10.1245/s10434-026-20848-1","url":null,"abstract":"Background: Patients with clinically node-positive (cN1) breast cancer represent a heterogeneous population with evolving axillary management strategies. We evaluated whether extent of axillary nodal involvement is associated with survival in cN1 disease.Methods: A retrospective study of patients with cT1-4N1M0 breast cancer and biopsy-proven axillary metastasis (2012-2018) was performed. All patients underwent axillary ultrasound (AUS) prior to neoadjuvant systemic therapy (NST) and again before surgery. Kaplan-Meier method and multivariable Cox proportional hazards models were used for statistical analysis.Results: Among 825 patients, most had cT2-3 (75.6%), hormone receptor-positive/HER2-negative (HR+/HER2-; 73%), ductal (89.7%) carcinoma. 64.1% (529) had 1-3 abnormal nodes on pretreatment AUS, whereas 35.9% had > 3 abnormal nodes. Definitive axillary surgery consisted of axillary lymph node dissection in 83.3% and sentinel node biopsy or targeted axillary dissection in 16.7%. Pathologic complete response (pCR) rate (breast and nodes) was 22.7%; breast-only and nodal-only pCR rates were 6.4% and 11.8%, respectively. At median follow-up of 5.6 years, 5-year overall survival, breast cancer-specific survival, and event-free survival were 92%, 94%, and 91%, respectively. Overall (breast and nodes), nodal-only, and breast-only pCR were prognostic across all survival outcomes. On multivariable analysis, age, triple negative subtype, cT4 tumors, lack of pCR, and > 3 abnormal nodes on pretreatment AUS were independent predictors of worse outcomes.Conclusions: Among patients with cN1 breast cancer receiving NST and surgery, long-term survival outcomes were excellent. Extent of pretreatment nodal involvement by AUS was prognostic and could help to determine treatment selection in patients with cN1 disease.","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-Term Survival After CRS-HIPEC for colorectal Cancer Peritoneal Metastases. CRS-HIPEC治疗结直肠癌腹膜转移后的长期生存率。

IF 3.8 2区医学

Annals of Surgical Oncology Pub Date : 2026-11-07 DOI: 10.1245/s10434-026-20753-7

L J van Kesteren, A G J Aalbers, A Chakroun, L van der Snee, R Hompes, W Lameris, Karen Bolhuis, B A Grotenhuis, Susan van Dieren, T E Buffart, N F M Kok, J B Tuynman

{"title":"Long-Term Survival After CRS-HIPEC for colorectal Cancer Peritoneal Metastases.","authors":"L J van Kesteren, A G J Aalbers, A Chakroun, L van der Snee, R Hompes, W Lameris, Karen Bolhuis, B A Grotenhuis, Susan van Dieren, T E Buffart, N F M Kok, J B Tuynman","doi":"10.1245/s10434-026-20753-7","DOIUrl":"https://doi.org/10.1245/s10434-026-20753-7","url":null,"abstract":"Background: Most patients with colorectal cancer (CRC) and peritoneal metastases (PM) face a dismal prognosis. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a curative-intent treatment for patients with limited disease. This study assessed long-term survival and recurrence patterns.Methods: A consecutive cohort of patients with CRC-PM treated with CRS-HIPEC. Patients with complete macroscopic cytoreduction were eligible. Main outcomes were overall survival (OS), disease-free survival (DFS), peritoneal recurrence-free survival (PRFS) and recurrence patterns.Results: In total, 440 patients were evaluated over a median follow-up of 35.2 months (IQR 25.3-68.7). Induction systemic therapy was administered to 43.1% of patients. Median DFS was 9.7 months (95% CI 8.3-11.1), and median OS was 50.2 months (95% CI 44.3-56.2). Independent prognostic factors for decreased OS were Peritoneal Cancer Index (PCI) > 10, positive lymph node status (N-stage), ASA score > 2, and right-sided primary tumors. During follow-up, 71.4% of patients developed recurrent disease in the peritoneum (54.8%), lungs (22.9%), and liver (19.1%). Independent prognostic factors for decreased PRFS were lymph node metastases and higher PCI scores. Neither induction therapy nor HIPEC regimen was correlated with PRFS. Early metachronous presentation of peritoneal metastasis, also emerged as a significant adverse factor for OS, DFS and PRFS.Conclusions: Patients undergoing complete CRS-HIPEC achieved a favorable median OS exceeding 50 months, with approximately 30% of individuals exhibiting long-term survival indicative of cure. However, early recurrence remains a major problem and is in need for further research to improve CRS-HIPEC regimens.","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ASO Visual Abstract: Analysis of the Safety and Efficacy of Cryoablation for Patients with Locally Advanced Pancreatic Cancer. 摘要：局部晚期胰腺癌冷冻消融治疗的安全性和有效性分析。

IF 3.8 2区医学

Annals of Surgical Oncology Pub Date : 2026-11-07 DOI: 10.1245/s10434-026-20840-9

Shutong Shao, Li Wang, Feng Tan, Shengzhong Hou, Kang Xue, Xing Huang, Dan Cao, Junjie Xiong, Bole Tian

引用次数: 0

ASO Visual Abstract: Extent of Lymph Node Examination in Older Adults with Gastric Adenocarcinoma: Is There a Tradeoff between Survival and Short-term Outcomes? 老年胃腺癌患者的淋巴结检查范围：生存和短期预后之间是否存在权衡？

IF 3.8 2区医学

Annals of Surgical Oncology Pub Date : 2026-11-07 DOI: 10.1245/s10434-026-20855-2

Ann L Kim, Bryant Morocho, Steve Kwon

引用次数: 0

CARG Score Predicts Perioperative Chemotherapy Completion in Pancreatic Cancer: Association of Completion with Overall Survival. CARG评分预测胰腺癌围手术期化疗完成：完成与总生存期的关系。

IF 3.8 2区医学

Annals of Surgical Oncology Pub Date : 2026-11-07 DOI: 10.1245/s10434-026-20864-1

Naoki Iwanaga, Yoshinori Takeda, Atsushi Takahashi, Haruka Tanaka, Shoichi Irie, Hirofumi Ichida, Ryuji Yoshioka, Yoshihiro Mise, Yoshihito Kotera, Akio Saiura

{"title":"CARG Score Predicts Perioperative Chemotherapy Completion in Pancreatic Cancer: Association of Completion with Overall Survival.","authors":"Naoki Iwanaga, Yoshinori Takeda, Atsushi Takahashi, Haruka Tanaka, Shoichi Irie, Hirofumi Ichida, Ryuji Yoshioka, Yoshihiro Mise, Yoshihito Kotera, Akio Saiura","doi":"10.1245/s10434-026-20864-1","DOIUrl":"https://doi.org/10.1245/s10434-026-20864-1","url":null,"abstract":"Background: Neoadjuvant chemotherapy (NAC) followed by surgery and adjuvant chemotherapy (AC) is the standard treatment strategy for resectable (R) and borderline resectable with venous involvement (BR-PV) pancreatic cancer (PC). However, the survival impact of completion of perioperative chemotherapy (CPC) remains unclear. We evaluated the association between CPC and overall survival (OS) and whether the Cancer and Aging Research Group (CARG) score, a tool for predicting chemotherapy-related toxicity, could predict CPC.Patients and methods: We retrospectively reviewed a treatment-initiated cohort of patients with R or BR-PV PC who started NAC between 2019 and 2023, regardless of receipt of surgery. CPC was defined as achieving relative total dose intensity (RTDI) ≥ 80% during NAC and RTDI ≥65% during AC. Landmark Cox models starting at L2 (L2: surgery + 34 weeks) were used for OS, with multivariable adjustment for prespecified covariates. Multivariable logistic regression was used to identify predictors of CPC based on clinical variables prior to NAC.Results: Among 122 patients 52 (42.6%) achieved CPC. Among 102 patients who reached the L2 landmark, OS was significantly longer in the CPC group than in the non-CPC group (5-year, 42.8% versus 29.8%; log-rank P = 0.022). In multivariable landmark Cox analysis, non-CPC was independently associated with worse OS (HR 2.708; P = 0.008). In multivariable logistic regression, a high CARG score was independently associated with a lower likelihood of CPC (OR 0.204; P = 0.021).Conclusions: CPC was associated with improved OS. The CARG score may help identify patients at risk of failing to complete perioperative chemotherapy.","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgical Outcomes in Patients with Ovarian Growing Teratoma Syndrome: Experience from a Tertiary Center. 卵巢生长畸胎瘤综合征患者的手术结果：来自三级中心的经验。

IF 3.8 2区医学

Annals of Surgical Oncology Pub Date : 2026-11-07 DOI: 10.1245/s10434-026-20779-x

Dan Wang, Pengrui Tang, Congwei Jia, Ruojiao Wang, Jiaxin Yang, Jie Yang, Peng Peng, Dongyan Cao, Junjun Yang, Yang Xiang

{"title":"Surgical Outcomes in Patients with Ovarian Growing Teratoma Syndrome: Experience from a Tertiary Center.","authors":"Dan Wang, Pengrui Tang, Congwei Jia, Ruojiao Wang, Jiaxin Yang, Jie Yang, Peng Peng, Dongyan Cao, Junjun Yang, Yang Xiang","doi":"10.1245/s10434-026-20779-x","DOIUrl":"https://doi.org/10.1245/s10434-026-20779-x","url":null,"abstract":"Objective: To evaluate the surgical outcomes in a large series of patients with growing teratoma syndrome (GTS).Methods: We conducted a retrospective study of patients with GTS treated at a tertiary center between 2000 and 2025.Results: A total of 63 patients were included in the current study. The median age at diagnosis of GTS was 25.5 years (range 7-55 years). The median interval between the initial diagnosis of ovarian immature teratoma and the occurrence of GTS was 12.3 months (range 4-367 months). Growing teratoma syndrome developed during adjuvant chemotherapy in 30/63 (47.6%), after chemotherapy in 27/63 (42.9%), and after initial surgery without chemotherapy in 6/63 (9.5%). Complete resection was achieved in 38 patients, and fertility-sparing surgery (FSS) was performed in 50 patients. Seventeen patients experienced at least one recurrence during a median follow-up period of 44 months (range 4-196 months) after initial treatment of GTS. The presence of residual disease after the initial surgery for GTS was the only factor associated with GTS recurrence (P < 0.001). Analysis of risk factors for GTS recurrence revealed no significant difference in relapse rates between FSS and radical surgery patients (30% vs 15.4%, P = 0.290). Seven of nine patients who desired pregnancy subsequently had nine spontaneous pregnancies.Conclusions: The overall prognosis of ovarian GTS is favorable. Optimal debulking surgery should be performed to reduce the possibility of recurrence. Fertility-sparing surgery appears feasible in carefully selected patients who wish to preserve their fertility, after comprehensive counseling on the risk of recurrence.","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ASO Author Reflections: Addressing Surgical Delays for Neighboring Hawaiian Island Breast Cancer Patients. ASO作者反思：解决邻近夏威夷岛乳腺癌患者的手术延误问题。

IF 3.8 2区医学

Annals of Surgical Oncology Pub Date : 2026-11-07 DOI: 10.1245/s10434-026-20888-7

Doris Yang, Sarah Abdul-Ghani, Marissa Miyagi, Hideko Yamauchi, Ashley Marumoto

引用次数: 0

ASO Author Reflections: Beyond the Tumor: Host Nutrition and Immune Status as Prognostic Marker After Curative Surgery for Gallbladder Cancer. ASO作者反思：超越肿瘤：宿主营养和免疫状态作为胆囊癌手术后预后指标。

IF 3.8 2区医学

Annals of Surgical Oncology Pub Date : 2026-11-07 DOI: 10.1245/s10434-026-20808-9

Shraddha Patkar, Karan D Kale, Mufaddal Kazi, Mahesh Goel

引用次数: 0

Editorial Comment: Drawing Blood is the Easy Part-A New Blood Test for Colorectal Cancer Screening. 编辑评论：抽血是简单的部分——一种新的结肠直肠癌筛查血液检测方法。

IF 3.8 2区医学

Annals of Surgical Oncology Pub Date : 2026-11-06 DOI: 10.1245/s10434-026-20884-x

Jaydeep Mahasamudram, William A Ross

引用次数: 0

Tailored Approach for Portal Vein Involvement with a Replaced Right Hepatic Artery during Robotic Pancreatoduodenectomy. 机器人胰十二指肠切除术中门静脉受累更换右肝动脉的定制入路。

IF 3.8 2区医学

Annals of Surgical Oncology Pub Date : 2026-11-06 DOI: 10.1245/s10434-026-20863-2

Koichi Tomita, Adriana Gamboa, Jessica E Maxwell, Rebecca A Snyder, Michael P Kim, Ching-Wei D Tzeng, Matthew H G Katz, Naruhiko Ikoma

{"title":"Tailored Approach for Portal Vein Involvement with a Replaced Right Hepatic Artery during Robotic Pancreatoduodenectomy.","authors":"Koichi Tomita, Adriana Gamboa, Jessica E Maxwell, Rebecca A Snyder, Michael P Kim, Ching-Wei D Tzeng, Matthew H G Katz, Naruhiko Ikoma","doi":"10.1245/s10434-026-20863-2","DOIUrl":"https://doi.org/10.1245/s10434-026-20863-2","url":null,"abstract":"In robotic pancreatoduodenectomy (RPD) for tumors with portal vein (PV) involvement and a replaced right hepatic artery (rRHA), precise dissection from the posterior aspect of the pancreatic head is not always straightforward. Therefore, an anterior and inferior approach may be more appropriate in the robotic setting. The rRHA should be identified at both its proximal and distal ends (at its origin from the superior mesenteric artery [SMA] and along the right side of the bile duct within the hepatoduodenal ligament, respectively) and dissected from both sides to the greatest extent feasible.1 The key principle is to obtain proximal and distal control of the rRHA before approaching the most adherent portion of the tumor. Unlike standard RPD, the presence of an rRHA requires early identification and vascular control from both its proximal and distal sides before PV/superior mesenteric vein (SMV) dissection because the artery may limit posterior exposure and is at risk during dissection of the tumor from the portomesenteric vein.","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0